By Brad Dunn — Canadian nonprofit TheraPsil is leading a new patient-based lawsuit against the federal government to expand access to psilocybin and related therapies — a case it believes will open the door to national legalization of psychedelics. Last week, seven patients and one healthcare practitioner filed a charter challenge claiming the country’s stringent […]
By reMind Staff — The Diaspora Psychedelic Society has launched two new programs in Jamaica aimed at easing the anxiety and depression associated with life-threatening illnesses and the dying process: Sacred Transitions End-of-Life Retreats and Psychedelic End-of-Life Doula Training. The Sacred Transitions End-of-Life Retreat offers psilocybin explorations with facilitated discussions on the topics of death […]
By reMind Staff — Investment firm Morgan Stanley has released an upbeat analysis of the emerging marketplace for psychedelic medicines and therapies. The report, written by the firm’s Counterpoint Global team of analysts, says the impact of breakthrough psychedelic drugs could far exceed current expectations: “Beyond mental illness and pain-related diseases, psychedelics have the potential […]
By Brad Dunn — Officials have urged the Biden administration to prepare for the likelihood that the FDA will approve MDMA and psilocybin for breakthrough therapies within the next two years. In correspondence made public between the U.S. Dept of Health and Human Services and Rep. Madeleine Dean (D-Pa.), the administration indicated it is “exploring […]
By reMind Staff — Marking a victory for psychedelics advocates, the Drug Enforcement Agency announced Friday it was withdrawing its proposal to place five more tryptamines in schedule I of the Controlled Substances Act. The reversal follows intense pushback from psychedelics researchers, legal experts and the general public over the agency’s proposal in January to […]